Chris Paradise, Ph.D.

Chris Paradise, Ph.D. has a diverse work experience spanning various roles and companies. From 2020 to the present, they have served as the Vice President of Research and Development at Rion, where they lead and oversees research initiatives. Prior to this, they worked as a Senior Research Scientist at Rion from 2021 to 2022, contributing to the development of exosome-based therapeutics for regeneration. From 2016 to 2020, Chris was a Predoctoral Candidate at Mayo Clinic, focusing on their doctoral research. Chris also gained valuable experience as a GREP Student and Research Trainee at Mayo Clinic from 2014 to 2016, enhancing their research skills. Overall, Chris Paradise, Ph.D. has a strong background in research and development, particularly in the field of regenerative therapies.

Chris Paradise, Ph.D. completed their education at Mayo Clinic Graduate School of Biomedical Sciences from 2016 to 2020. During this time, they obtained a Doctor of Philosophy (Ph.D.) degree in Molecular Pharmacology and Experimental Therapeutics. Prior to that, from 2010 to 2014, they attended St. Olaf College and earned a Bachelor of Arts (BA) degree in Biology, General.